[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[$esaiy](/topic/$esaiy)

### Top Social Posts

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"$RHHBY $LLY $BIIB $ESAIY Roche Lilly Win First FDA Nod for Alzheimers Blood Test for Primary Care Use"  
[X Link](https://x.com/MarcJacksonLA/status/1978098981080072615) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2025-10-14T14:02Z 7587 followers, XXX engagements


"$BIOA $ESAIY Leqembi Iqlik (lecanemab-irmb) maintenance treatment launched in the United States BioArctic partner Eisai launched Leqembi Iqlik (lecanemab-irmb) subcutaneous autoinjector in the U.S. on October X 2025 as a maintenance option for early Alzheimers disease (MCI or mild dementia) after an initial 18-month IV induction. After XX months of XX mg/kg IV every two weeks patients may continue IV every four weeks or switch to a weekly XXX mg at-home subcutaneous injection. The company also launched a Leqembi Companion program with nurse education financial/insurance support an injection"  
[X Link](https://x.com/MarcJacksonLA/status/1975332616623825261) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2025-10-06T22:49Z 7586 followers, XXX engagements


"$BIOA $ESAIY Leqembi approved for IV maintenance treatment in China BioArctic announced that its partner Eisai has received approval from China's NMPA for Leqembi's (lecanemab) IV maintenance treatment in early Alzheimer's disease. The new approval allows for a maintenance dosing regimen of XX mg/kg once every four weeks after an 18-month initiation phase of bi-weekly dosing. Leqembi initially approved in China in January 2024 is notable as the only approved therapy targeting both amyloid plaque and protofibrils in Alzheimer's disease treatment. The drug was developed through a collaboration"  
[X Link](https://x.com/MarcJacksonLA/status/1972551114496393485) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2025-09-29T06:36Z 7586 followers, XXX engagements


"$BIIB $ESAIY LEQEMBI (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimers Disease Approved in China Biogen's and Eisai's Alzheimer's treatment LEQEMBI (lecanemab) was approval in China for once-every-four-weeks intravenous maintenance dosing. The approval follows the initial January 2024 authorization for treating early Alzheimer's disease patients with mild cognitive impairment or mild dementia. Maintenance dosing allows patients to transition from the initial bi-weekly XX mg/kg dosing to a more convenient monthly schedule after XX months of treatment. LEQEMBI is notable"  
[X Link](https://x.com/MarcJacksonLA/status/1972451765766475984) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2025-09-29T00:02Z 7586 followers, XXX engagements